CRYPTOCOCCOSIS TREATMENT MARKET ANALYSIS

Market News

 Key Developments

1. Major market players are involved in different business strategies such as gaining product approval from regulatory authorities, in order to gain competitive edge in the global market. For instance, in February 2019, Amplyx Pharmaceuticals, a U.S.-based pharmaceutical company, received orphan drug designation for APX001 from the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development. This drug will be used for the treatment of cryptococcosis.
2. Key market players are focused on different business strategies such as product launches, in order to gain competitive edge in the global market. For instance, in January 2018, Lupin Limited, an Indian pharmaceutical company, launched generic version of Valeant Pharmaceutical International Inc.’s ‘Ancobon Capsules’. These capsules are indicated for infections caused by Cryptococcus.